INCB040093

DRUG2 trials

Sponsors

Incyte Corporation

Conditions

B-cell MalignanciesRecurrent Adult Hodgkin's LymphomaRefractory Hodgkin Lymphoma

Phase 1

Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies

CompletedNCT01905813

Incyte CorporationB-cell Malignancies

Start: 2013-06-30End: 2026-02-26Updated: 2026-05-11

Phase 2

INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma

TerminatedNCT02456675

Incyte CorporationRecurrent Adult Hodgkin's Lymphoma, Refractory Hodgkin Lymphoma

Start: 2015-06-30End: 2016-12-16Updated: 2018-01-12

Related Papers

Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma

Blood2018-04-2551 citations

A phase 1 study of INCB040093, a PI3Kδ inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor: Interim results from patients (pts) with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL).

Journal of Clinical Oncology2015-05-2010 citations

Interim analysis of a phase I study of INCB040093, a PI3Kδ inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor, in patients (pts) with relapsed or refractory (r/r) B-cell malignancies.

Journal of Clinical Oncology2015-05-208 citations